MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

Christian Steidl, Sohrab P. Shah, Bruce W. Woolcock, Lixin Rui, Masahiro Kawahara, Pedro Farinha, Nathalie A. Johnson, Yongjun Zhao, Adele Telenius, Susana Ben Neriah, Andrew McPherson, Barbara Meissner, Ujunwa C. Okoye, Arjan Diepstra, Anke Van Den Berg, Mark Sun, Gillian Leung, Steven J. Jones, Joseph M. Connors, David G. HuntsmanKerry J. Savage, Lisa M. Rimsza, Douglas E. Horsman, Louis M. Staudt, Ulrich Steidl, Marco A. Marra, Randy D. Gascoyne

Research output: Contribution to journalArticlepeer-review

461 Scopus citations

Fingerprint

Dive into the research topics of 'MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers'. Together they form a unique fingerprint.

Medicine & Life Sciences